

## DESCRIPTION

<b>Species Reactivity</b>	Mouse
<b>Specificity</b>	Detects the $\alpha$ subunit of mouse HGF R/c-MET in direct ELISAs and Western blots.
<b>Source</b>	Monoclonal Rat IgG <sub>2A</sub> Clone # 118624
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	<i>S. frugiperda</i> insect ovarian cell line Sf 21-derived recombinant mouse HGF R/c-MET Glu25-Asn929 Accession # P16056
<b>Endotoxin Level</b>	<0.10 EU per 1 $\mu$ g of the antibody by the LAL method.
<b>Formulation</b>	Lyophilized from a 0.2 $\mu$ m filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 $\mu$ m filtered solution in PBS.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
<b>Western Blot</b>	1 $\mu$ g/mL	Recombinant Mouse HGF R/c-MET Fc Chimera (Catalog # 527-ME)

## PREPARATION AND STORAGE

<b>Reconstitution</b>	Reconstitute at 0.5 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>● 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>● 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>● 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

## BACKGROUND

HGF R, also known as Met (from *N*-methyl-*N*-nitro-*N*-nitrosoguanidine induced), is a glycosylated receptor tyrosine kinase that plays a central role in epithelial morphogenesis and cancer development. HGF R is synthesized as a single chain precursor which undergoes cotranslational proteolytic cleavage. This generates a mature HGF R that is a disulfide-linked dimer composed of a 50 kDa extracellular  $\alpha$  chain and a 145 kDa transmembrane  $\beta$  chain (1, 2). The extracellular domain (ECD) contains a seven bladed  $\beta$ -propeller sema domain, a cysteine-rich PSI/MRS, and four Ig-like E-set domains, while the cytoplasmic region includes the tyrosine kinase domain (3, 4). An alternately spliced form of mouse HGF R lacks a cytoplasmic juxtamembrane region important for regulation of signal transduction (5, 6). The sema domain, which is formed by both the  $\alpha$  and  $\beta$  chains of HGF R, mediates both ligand binding and receptor dimerization (3, 7). Ligand-induced tyrosine phosphorylation in the cytoplasmic region activates the kinase domain and provides docking sites for multiple SH2-containing molecules (8, 9). HGF stimulation induces HGF R down-regulation *via* internalization and proteasome-dependent degradation (10). In the absence of ligand, HGF R forms noncovalent complexes with a variety of membrane proteins including CD44v6, CD151, EGF R, Fas, integrin  $\alpha$ 6/ $\beta$ 4, plexins B1, 2, 3, and MSP R/Ron (11-18). Ligation of one complex component triggers activation of the other, followed by cooperative signaling effects (11-18). Formation of some of these heteromeric complexes is a requirement for epithelial cell morphogenesis and tumor cell invasion (11, 15, 16). Paracrine induction of epithelial cell scattering and branching tubulogenesis results from the stimulation of HGF R on undifferentiated epithelium by HGF released from neighboring mesenchymal cells (19). Genetic polymorphisms, chromosomal translocation, overexpression, and additional splicing and proteolytic cleavage of HGF R have been described in a wide range of cancers (1). Within the ECD, mouse HGF R shares 87%, 87%, and 94% amino acid sequence identity with canine, human, and rat HGF R, respectively.

## References:

1. Birchmeier, C. *et al.* (2003) *Nat. Rev. Mol. Cell Biol.* **4**:915.
2. Corso, S. *et al.* (2005) *Trends Mol. Med.* **11**:284.
3. Gherardi, E. *et al.* (2003) *Proc. Natl. Acad. Sci.* **100**:12039.
4. Chan, A.M. *et al.* (1988) *Oncogene* **2**:593.
5. Lee, C-C. and K.M. Yamada (1994) *J. Biol. Chem.* **269**:19457.
6. Lee, C-C., *et al.* (1995) *J. Biol. Chem.* **270**:507.
7. Kong-Beltran, M. *et al.* (2004) *Cancer Cell* **6**:75.
8. Naldini, L. *et al.* (1991) *Mol. Cell. Biol.* **11**:1793.
9. Ponzetto, C. *et al.* (1994) *Cell* **77**:261.
10. Jeffers, M. *et al.* (1997) *Mol. Cell. Biol.* **17**:799.
11. Orian-Rousseau, V. *et al.* (2002) *Genes Dev.* **16**:3074.
12. Klosek, S.K. *et al.* (2005) *Biochem. Biophys. Res. Commun.* **336**:408.
13. Jo, M. *et al.* (2000) *J. Biol. Chem.* **275**:8806.
14. Wang, X. *et al.* (2002) *Mol. Cell* **9**:411.
15. Trusolino, L. *et al.* (2001) *Cell* **107**:643.
16. Giordano, S. *et al.* (2002) *Nat. Cell Biol.* **4**:720.
17. Conrotto, P. *et al.* (2004) *Oncogene* **23**:5131.
18. Follenzi, A. *et al.* (2000) *Oncogene* **19**:3041.
19. Sonnenberg, E. *et al.* (1993) *J. Cell Biol.* **123**:223.